Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium

Sanjosé, Sílvia de; Benavente, Yolanda; Vajdic, Claire M.; Engels, Eric A.; Morton, Lindsay M.; Bracci, Paige M.; Spinelli, John J.; Zheng, Tongzhang; Zhang, Yawei; Franceschi, Silvia; Talamini, Renato; Holly, Elizabeth A.; Grulich, Andrew E.; Cerhan, James R.; Hartge, Patricia; Cozen, Wendy; Boffetta, Paolo; Brennan, Paul; Maynadié, Marc; Cocco, Pierluigi; Bosch, Ramón; Foretová, Lenka; Staines, Anthony; Becker, Nikolaus; Nieters, Alexandra

doi:10.1016/j.cgh.2008.02.011

Cited by 317 publications

(263 citation statements)

References 48 publications

Supporting

Mentioning

236

Contrasting

Unclassified

Order By: Relevance

“…In accordance with de Sanjose et al [7] , we found a high prevalence of HCV-positives (19%) among DBLC and indolent lymphoma patients. We observed that DLBCL patients had a history suggestive of a short duration of HCV infection, and a higher prevalence of genotype 1, as compared to patients with indolent, low-grade B-NHL, who had a higher prevalence of genotype 2.…”

Section: Discussionsupporting

confidence: 75%

“…However, studies conducted in countries with a lower prevalence of HCV infection also found a possible positive association between HCV and risk of developing B-NHL [6] . In a large pooled analysis of combined data from several countries, de Sanjose et al [7] demonstrated that presence of HCV infection was linked not only to marginal zone lymphoma, considered an indolent course B-NHL, but also to diffuse large B-cell lymphoma (DLBCL), a high-grade B-NHL. However, the strongest argument for a causative role of HCV infection in lymphoproliferative disease derives from interventional studies where antiviral regimen directed to HCV were successful in achieving the cure of HCV-related B-NHL [8][9][10][11] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma

Pellicelli

Marignani²,

Zoli

et al. 2011

WJH

View full text Add to dashboard Cite

AIM:To evaluate if indolent B cell-non Hodgkin's lymphoma (B-NHL) and diffuse large B-cell lymphoma (DL-BCL) in hepatitis C virus (HCV) positive patients could have different biological and clinical characteristics requiring different management strategies. METHODS:A group of 24 HCV related B-NHL patients (11 indolent, 13 DLBCL) in whom the biological and clinical characteristics were described and confronted. Patients with DLBCL were managed with the standard of care of treatment. Patients with indolent HCV-related B-NHL were managed with antiviral treatment pegylated interferon plus ribavirin and their course observed. The outcomes of the different approaches were compared. RESULTS:Patients with DLBCL had a shorter duration of HCV infection and a higher prevalence of HCV genotype 1 compared to patients with indolent B-NHL in which HCV genotype 2 was the more frequent genotype. Five of the 9 patients with indolent HCV-related

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma

Pellicelli

Marignani²,

Zoli

et al. 2011

WJH

View full text Add to dashboard Cite

show abstract

“…First, although we adjusted for age, sex, alcohol intake and smoking, we did not consider residual confounding by other known or unknown risk factors, including socioeconomic status, history of autoimmune disorders, immunodeficiency syndromes 40,41 and viral infections. 42,43 Second, the impact of recent weight and BMI on ML risk may have been underestimated. Recent weight before onset of symptoms as selfreported by case subjects may have been affected by the presence of latent lymphoma, when the patient may not have associated weight changes with their disease.…”

Section: Discussionmentioning

confidence: 99%

Association between obesity and the risk of malignant lymphoma in Japanese: a case–control study

Kanda

Matsuo

Suzuki

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

Although marked differences in anthropometric characteristics and malignant lymphoma (ML) incidence suggest that the association between obesity and ML risk in Asian and non-Asian populations may differ, few studies have investigated this association in Asian populations. Here, we conducted a sex-and age-matched case-control study in a Japanese population using 782 cases and 3,910 noncancer controls in the hospital-based Epidemiological Research Program at Aichi Cancer Center Hospital. Odds ratios (ORs) and 95% confidence intervals (CIs) for anthropometric characteristics were estimated using a conditional logistic regression model that incorporated smoking and alcohol intake. Recent body weight and body mass index (BMI) showed marginally significant association with ML risk (ORs [95% CIs] per 5-unit increase in recent weight and BMI; 1.04 [0.99-1.09] and 1.11 [0.98-1.27], respectively). On the other hand, weight and BMI in early adulthood exhibited a strong association with ML risk (ORs [95% CIs] per 5-unit increase in early adulthood weight and BMI; 1.11 [1.05-1.18] and 1.33 [1.13-1.55], respectively). Further, in women, a BMI of 25.0-29.9 kg/m 2 , defined as obesity in Asian populations, during early adulthood was significantly associated with ML risk compared to the normal range of 18.5-22.9 kg/m 2 . By histological ML subtype, the point estimates of ORs for obesity relative to normal weight in early adulthood were over unity for nonHodgkin lymphoma (NHL) as a whole and significant for diffuse large B-cell lymphoma (DLBCL). In conclusion, our study in Japanese subjects suggested that early adulthood obesity is associated with the risk of NHL, particularly DLBCL.Although the association between obesity and the risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has been investigated in a number of case-control and cohort studies, results have been inconsistent. 1-11 Moreover, most of these studies were conducted in non-Asian populations. Recently, the International Lymphoma Epidemiology Consortium (InterLymph) reported a large pooled analysis of 18 case-control studies conducted at various centers, including ours, to evaluate the impact of recent obesity on NHL risk, with the results suggesting no significant association between NHL and obesity. 1 In contrast, Maskarinec et al. 2 reported that body weight and body mass index (BMI) at age 21 were stronger predictors of NHL risk than baseline anthropometric characteristics, suggesting that weight during early adulthood may be a better indicator of NHL risk than weight at an older age. Further, increase in various cytokines among obese people has been proposed as a mechanism underlying the development of malignant lymphoma (ML); bioavailable insulin-like growth factor-1 (IGF-1) and insulin play a role in promoting cellular proliferation and inhibiting apoptosis, 12-14 whereas leptin is considered to be involved in lymphomagenesis via inflammatory pathways. [15][16][17][18][19] Because Asian populations generally have a low BMI but higher

show abstract

“…There is a two-to four-fold increased risk of developing B-NHL among HCV-positive patients [1][2][3][4]. In comparison to their negative counterparts, HCV-associated B-NHL (i) are more often marginal zone lymphomas (MZL) and diffuse large B-cell lymphomas (DLBCL) [4], (ii) often display extranodal localization [3], (iii) and have higher rates of liver toxicity after treatment by chemotherapy [5][6][7][8]. HCV-associated lymphomas have also been shown to be frequently associated with type II mixed cryoglobulinemia (MC) [9,10], which are immunoglobulin complexes containing both a polyclonal IgG and a monoclonal IgM rheumatoid factor (RF) directed against the IgG.…”

Section: Introductionmentioning

confidence: 99%

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

et al. 2014

View full text Add to dashboard Cite

on behalf of the ANRS HC-13 Lympho-C Study Group Hepatitis C virus (HCV) infection increases the risk of B-cell non-Hodgkin lymphomas (B-NHL). Antiviral treatment (AT) can induce hematological responses in patients with marginal zone lymphomas (MZL). The ANRS HC-13 Lympho-C study aimed at a better understanding of the impact of AT on HCV associated B-NHL. This multicentric study enrolled 116 HCV-positive patients with B-NHL between 2006 and 2012. Cytological and histological samples were collected for centralized review. At lymphoma diagnosis, median age was 61 years and gender ratio M/F was 1. Cytohistological distribution was marginal zone lymphoma (MZL) n 5 45 (39%), diffuse large B-cell lymphoma (DLBCL) n 5 45 (39%), and other types n 5 26 (22%). MZL patients had more frequent detection of rheumatoid factor (68% vs. 35%; P 5 0.001) and more frequently mixed cryoglobulinemia (74% vs. 44%; P 5 0.021) than patients with DLBCL. Among patients receiving AT, a sustained virologic response was achieved in 23 of 38 (61%) patients with MZL and in 9 of 17 (53%) with DLBCL (P 5 0.42). Three-year overall survival (OS) and progression-free survival were 78% 95%CI and 64% , respectively, without difference between cytohistological groups. Outcome analysis showed a favorable association between OS and AT in all patients (P 5 0.05) and in the subgroup of MZL patients only (P 5 0.04). Our data support that AT improves the outcomes of HCV-associated NHLs. The impact of new AT regimen with protease inhibitor needs to be investigated in this setting. [clinicalTrials.gov Identification number NCT01545544]Am.

show abstract

Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium

Abstract: Background & Aims-Increasing evidence points towards a role of hepatitis C virus (HCV) infection in causing malignant lymphomas. We pooled case-control study data to provide robust estimates of the risk of non-Hodgkin's lymphoma (NHL) subtypes after HCV infection.

Cited by 317 publications

References 48 publications

Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma

Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma

Association between obesity and the risk of malignant lymphoma in Japanese: a case–control study

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Contact Info

Product

Resources

About